翔宇医疗(688626) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥186,048,007.84, representing a 10.02% increase compared to ¥169,097,488.82 in the same period last year[4] - Net profit attributable to shareholders decreased by 41.26% to ¥22,951,013.60 from ¥39,073,828.52 year-on-year[4] - The net profit after deducting non-recurring gains and losses fell by 48.72% to ¥18,708,109.46 compared to ¥36,482,745.51 in the previous year[4] - Basic earnings per share decreased by 40.00% to ¥0.15 from ¥0.25 year-on-year[4] - Net profit for Q1 2025 was ¥22,372,121.70, a decrease of 42.3% from ¥38,725,982.66 in Q1 2024[21] Research and Development - Research and development expenses totaled ¥38,245,456.20, an increase of 29.37% from ¥29,562,422.95, accounting for 20.56% of operating revenue[5] - The company is focusing on enhancing its capabilities in brain-computer interfaces and rehabilitation robotics, which has led to increased R&D and sales expenses[7] - Research and development expenses for Q1 2025 amounted to ¥38,245,456.20, an increase of 29.4% from ¥29,562,422.95 in Q1 2024[20] Cash Flow and Financing Activities - The net cash flow from operating activities was ¥20,844,216.27, up 20.52% from ¥17,295,631.36 in the previous year[4] - Cash inflow from operating activities totaled ¥238,724,034.47 in Q1 2025, compared to ¥175,052,571.80 in Q1 2024[22] - The company incurred a net cash outflow from investing activities of ¥184,841,430.36 in Q1 2025, compared to a net outflow of ¥129,823,616.21 in Q1 2024[22] - Cash inflow from financing activities totaled $508,939,160, an increase from $267,000,000 in the previous period, representing a 90.5% growth[24] - Cash outflow from financing activities amounted to $316,171,080.96, compared to $61,860,373.09 previously, indicating a significant increase[24] - Net cash flow from financing activities was $192,768,079.04, slightly down from $205,139,626.91 in the prior period[24] - The net increase in cash and cash equivalents was $28,790,032.07, a decrease from $92,604,587.47 year-over-year[24] - The ending balance of cash and cash equivalents was $731,702,584.50, compared to $744,371,900.04 in the previous period[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,106,935,592.27, a 6.12% increase from ¥2,927,874,338.81 at the end of the previous year[5] - The total current assets increased to approximately RMB 1.30 billion as of March 31, 2025, compared to RMB 1.14 billion at the end of 2024, representing a growth of about 14%[15] - The company reported a short-term loan of approximately RMB 580.20 million, an increase from RMB 354.10 million in the previous period, reflecting a rise of about 64%[16] - The company’s total liabilities increased to approximately RMB 919.14 million, compared to RMB 734.71 million, marking an increase of about 25%[16] - Total liabilities increased to ¥1,058,127,258.99 in the current period from ¥873,096,802.37 in the previous period[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,895[9] - Total equity attributable to shareholders decreased to ¥2,033,288,822.86 from ¥2,038,679,134.12[17] Awards and Recognition - The company was recognized as a "National Specialized and Innovative" small giant enterprise in the sports field[12] - The company received the "Innovation Development Practice Base" award in the medical and health industry[12] - The company participated in projects that won significant awards, including the first prize in the Anhui Provincial Science and Technology Progress Award for a wearable rehabilitation robot system[12] - The company achieved a total of 359 medical device registration certificates and filings, with 13 new additions during the reporting period[12] - The company obtained 52 new patents, including 11 invention patents, bringing the total to 1,954 patents[12]